169 related articles for article (PubMed ID: 8964443)
1. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].
Thomssen C
Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of advanced breast cancer].
Ogawa M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):769-74. PubMed ID: 1605652
[TBL] [Abstract][Full Text] [Related]
3. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
4. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
5. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
6. [Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].
Elling D; Krocker J; Kümmel S; Blohmer J; Lichtenegger W; Kohls A; Heinrich J; Quass J; Breitbach P; Köhler U
Zentralbl Gynakol; 2000; 122(4):207-16. PubMed ID: 10795118
[TBL] [Abstract][Full Text] [Related]
7. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
8. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Coccaro M; Gallucci G
J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567
[No Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
10. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
[TBL] [Abstract][Full Text] [Related]
11. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
[TBL] [Abstract][Full Text] [Related]
12. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
14. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
15. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
Albain KS
J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
[No Abstract] [Full Text] [Related]
17. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
Focan C; Beauduin M; Salamon E; de Greve J; de Wasch G; Lobelle JP; Majois F; Tagnon A; Tytgat J; van Belle S; Vandervellen R; Vindevoghel A;
Br J Cancer; 2001 Jul; 85(1):1-8. PubMed ID: 11437394
[TBL] [Abstract][Full Text] [Related]
18. Dose density in breast cancer: a simple message?
Lin NU; Gelman R; Winer EP
J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
[No Abstract] [Full Text] [Related]
19. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
20. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
